Cargando…
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Malignant melanoma is an aggressive type of skin cancer whose incidence is increasing globally. Although surgery is effective in early stage melanoma, patients with advanced melanoma only have a 20% 5-year survival rate. Hence, combinations of existing and new immunotherapy technologies and immunoth...
Autores principales: | Kuryk, Lukasz, Møller, Anne-Sophie W., Jaderberg, Magnus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343802/ https://www.ncbi.nlm.nih.gov/pubmed/30713786 http://dx.doi.org/10.1080/2162402X.2018.1532763 |
Ejemplares similares
-
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
por: Kuryk, Lukasz, et al.
Publicado: (2019) -
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
por: Kuryk, Lukasz, et al.
Publicado: (2018) -
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks
por: Kuryk, Lukasz, et al.
Publicado: (2019) -
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2023) -
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
por: Kuryk, Lukasz, et al.
Publicado: (2017)